PhaseBio Pharmaceuticals Inc.: Clinical Trials

4 completed, 3 terminated. 7 Phase 2, 1 Phase 1.

By phase and status

Phase	Trials	Status
Phase 2	7	Completed 4, Terminated 3
Phase 1	1	Completed 1

Follow PhaseBio Pharmaceuticals Inc.: new trials by email

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS). Pemziviptadil (PB1046), Low Dose (10 mg) Control - Acute Respiratory Distress Syndrome, Coronavirus	Phase 2	Terminated	PhaseBio Pharmaceuticals Inc.	54	2020-07-15	2020-12-11
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004 Pemziviptadil (PB1046) Injection - Pulmonary Arterial Hypertension	Phase 2	Terminated	PhaseBio Pharmaceuticals Inc.	25	2019-04-10	2022-02-22
Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH Pemziviptadil (PB1046) - Pulmonary Arterial Hypertension	Phase 2	Terminated	PhaseBio Pharmaceuticals Inc.	35	2018-07-15	2022-08-23
Study to Assess the Safety, Tolerability and PK/PD After 4 Weekly SC Injections of PB1046 in Subjects With Stable HFrEF PB1046 Injection, Placebo Injection - Heart Failure	Phase 2	Completed	PhaseBio Pharmaceuticals Inc.	29	2016-06-01	2022-07-14
Study to Assess the Safety, Tolerability, PK and PD Response of PE0139 Injection in Adult Subjects With T2DM PE0139 Injection, Placebo Injection - Type 2 Diabetes Mellitus	Phase 2	Completed	PhaseBio Pharmaceuticals Inc.	37	2015-10-01	2018-04-10
Phase 2b Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Assess the PD Response and Safety of Three Dose Levels of (PB1023) Injection Following 20 Weeks of Weekly SC Dosing in Adults With T2DM 50 mg PB1023, 70 mg PB1023, 100 mg PB1023 - Type 2 Diabetes Mellitus	Phase 2	Completed	PhaseBio Pharmaceuticals Inc.	593	2012-07-01	2015-12-07
Phase 1/2a, Randomized, Double-Blind, Placebo-Controlled, Study to Assess Safety, Tolerability, PK and PD Response of PB1023 Injection Following Single and Multiple SQ Doses in Adults With Type 2 Diabetes Mellitus Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl), Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl) - Diabetes Mellitus, Type 2	Phase 1 / Phase 2	Completed	PhaseBio Pharmaceuticals Inc.	80	2010-11-01	2013-05-21

Conditions studied

Diabetes Mellitus, Type 2 (3)  ·  Heart Failure (2)  ·  Pulmonary Arterial Hypertension (2)  ·  COVID-19 (1)  ·  Cardiovascular Diseases (1)  ·  Coronavirus Infections (1)  ·  Cytokine Release Syndrome (1)  ·  Dyspnea (1)  ·  Myocardial Infarction (1)  ·  Pneumonia (1)  ·  Pulmonary Edema (1)  ·  Respiratory Distress Syndrome (1)  ·  Respiratory Insufficiency (1)

Interventions

VIP-ELP fusion molecule PB1046 (4)  ·  Diet (1)  ·  Exercise (1)  ·  Injections (1)  ·  Injections, Subcutaneous (1)  ·  Liraglutide (1)  ·  Metformin (1)  ·  Sodium Chloride (1)  ·  Sulfonylurea Compounds (1)

Countries

United States (7)

Top investigators

Mark Matson, M.D. (1)